Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 3 July.

On the agenda this time are coronavirus vaccines, progress in NASH, the pricing of a new epilepsy drug and one multinational's efforts to assure investors of R&D progress.

Stories mentioned in this episode:

(Also see "Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine" - Scrip, 30 Jun, 2020.) 

(Also see "CanSino Coronavirus Vaccine Approved For Military Use In China" - Scrip, 29 Jun, 2020.)

(Also see "Intercept’s CRL Just Continues Upheaval In NASH" - Scrip, 29 Jun, 2020.)

(Also see "Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price" - Scrip, 28 Jun, 2020.)

(Also see "No Looking Back For Sanofi In R&D Turnaround Quest" - Scrip, 26 Jun, 2020.)


Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts